Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes

• Published in: Journal of Obesity & Metabolic Syndrome 2021, 30(3), 101, pp.233-247
• Main Authors: Rosenberg, Jared, Jacob, Jordan, Desai, Priya, Park, Jeremy, Donovan, Lorin, Kim, Joon Young
• Format: Article
• Language: English
• Subjects: glucagon-like peptide-1; glucose; glucose-dependent insulinotropic polypeptide; incretin; insulin; oral glucose tolerance test; Review; type 2 diabetes; 가정의학
• ISSN: 2508-6235; 2508-7576
• DOI: 10.7570/jomes21053

Type 2 diabetes (T2D) is a multifaceted metabolic disorder associated with distinctive pathophysiological disturbances. One of the pathophysiological risk factors observed in T2D is dysregulation of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both hormones stimulate insulin secretion by acting postprandially on pancreatic β-cell receptors. Oral glucose administration stimulates increased insulin secretion in comparison with isoglycemic intravenous glucose administration, a phenomenon known as the incretin effect. While the evidence for incretin defects in individuals with T2D is growing, the etiology behind this attenuated incretin effect in T2D is not clearly understood. Given their central role in T2D pathophysiology, incretins are promising targets for T2D therapeutics. The present review synthesizes the recent attempts to explain the biological importance of incretin hormones and explore potential pharmacological approaches that target the incretins.